#Germany #gene therapy #Cell Therapy #Minaris Advanced #Taufkirchen

Minaris Advanced Therapies Unveils New GMP Facility

On August 4, 2025, Minaris Advanced Therapies announced the grand opening of its state-of-the-art Good Manufacturing Practice (GMP) facility located in Taufkirchen, Germany. This strategic establishment aims to bolster the company's global production capabilities for advanced therapies, particularly in the burgeoning field of cell and gene therapy.

A Step Forward in Healthcare Innovation

As one of the leading global contract development and manufacturing organizations (CDMO) specializing in advanced therapies, Minaris has consistently prioritized innovation in its facilities. The new Taufkirchen site significantly amplifies their operational capacity and flexibility, ensuring they remain at the forefront of this rapidly evolving industry.

Dr. Orla Cloak, CEO of Minaris Advanced Therapies, remarked, "The opening of this facility marks a significant milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies worldwide. It enhances our presence in Europe and meets the growing demands of our clients in terms of speed, quality, and scalability."

Comprehensive Facility Features

The Taufkirchen facility boasts:

• - Six Class B/A cleanrooms for aseptic manufacturing.
• - A Class C cleanroom specifically designed for bioreactors and closed systems, which can be converted into Class A/B environments as needed.
• - Customizable cleanroom configurations and additional space of 224 m² (approximately 2411 ft²).
• - Independently controlled HVAC systems for each cleanroom suite to minimize downtime and support concurrent production activities.
• - Dedicated laboratories for process development and quality control.
• - Cryopreservation and storage facilities, along with enhanced security and alarm systems.

The presence of experienced staff from Minaris' nearby facility ensures that the new site benefits from extensive expertise in clinical and commercial manufacturing, process development, and analytics.

Strategic Advantages in Europe

Strategically located just minutes from Munich International Airport, this facility offers logistical advantages, making it easier for clients across Europe and beyond to access its services. Such logistical convenience is essential as the industry demands quick turnarounds and high-quality production for clinical trials and commercialization phases.

Iain Baird, Chairman of Minaris Advanced Therapies, stated, "This facility embodies our shared vision for the future of cell and gene therapy manufacturing—a scalable, flexible, and globally integrated approach. It is a testament to the dedication of our team in Germany and the strength of the Minaris-Altaris partnership, delivering long-term value to clients and patients around the world."

About Minaris Advanced Therapies

Minaris Advanced Therapies is a globally recognized CDMO and testing services provider specialized in cell and gene therapies. Headquartered in Philadelphia, Pennsylvania, the organization operates over 650,000 square feet of facilities across the USA, Europe, and Asia. To date, Minaris has produced and released more than 7,500 GMP batches, supporting therapy developers throughout early development, clinical trials, and commercial manufacturing. Minaris is part of the Altaris investment portfolio, which focuses on the healthcare sector and has invested in over 50 companies since 2003.

The successful launch of the Taufkirchen GMP facility underscores Minaris' commitment to enhancing therapeutic development and production, setting a new standard in the healthcare industry.

For further inquiries, contact: Tihesha Aaron
Email: [email protected]

Image Link
Logo Link